Specialty medical injectable drug program, requirements and drug policy updates for December
New specialty medical injectable updates and requirements announced December 2023.
Review the following tables to determine changes to our specialty medical injectable drug programs.
SPECIALTY MEDICAL INJECTABLE DRUGS ADDED TO REVIEW AT LAUNCH
For UnitedHealthcare Commercial business
| Drug Name | Treatment Uses |
|
Enzyme replacement therapy used for the prophylactic and on-demand treatment of adult and pediatric patients with congenital thrombotic thrombocytopenic purpura. |
Omvoh™ - IV formulation |
Used for the treatment of moderately to severely active ulcerative colitis in adults. |
Review the UnitedHealthcare Commercial Plan Review at Launch Medication List.
For questions, please contact your broker or UnitedHealthcare representative.
SPECIALTY MEDICAL INJECTABLE DRUGS ADDED TO MEDICATION SOURCING FOR OUTPATIENT HOSPITAL PROVIDERS ONLY
For UnitedHealthcare commercial business effective December 1, 2023
| Drug Name | Effective Date | Therapeutic Class | HCPCS Code(s) | Specialty Pharmacy |
| Izervay™ (avacincaptad pegol) |
1/1/24 | Complement inhibitor – ophthalmologic use | C9162 | Amber Specialty Pharmacy |
Review the UnitedHealthcare Commercial Plan Medication Sourcing List.
For questions, please contact your broker or UnitedHealthcare representative.
Share
